121 related articles for article (PubMed ID: 17266469)
21. Therapeutic advances in the treatment of brain metastases.
Chang JE; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Jan; 5(1):54-64. PubMed ID: 17339829
[TBL] [Abstract][Full Text] [Related]
22. Radiation therapy in the management of brain metastases from renal cell carcinoma.
Doh LS; Amato R; Paulino AC; Teh BS
Oncology (Williston Park); 2006 May; 20(6):603-13; discussion 613, 616, 619-20 passsim. PubMed ID: 16773845
[TBL] [Abstract][Full Text] [Related]
23. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay.
Donnelly ET; Liu Y; Paul TK; Rockwell S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1176-86. PubMed ID: 15990023
[TBL] [Abstract][Full Text] [Related]
24. Current strategies in whole-brain radiation therapy for brain metastases.
Mehta MP; Khuntia D
Neurosurgery; 2005 Nov; 57(5 Suppl):S33-44; discusssion S1-4. PubMed ID: 16237287
[TBL] [Abstract][Full Text] [Related]
25. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
26. Whole brain radiotherapy for the treatment of multiple brain metastases.
Tsao MN; Lloyd N; Wong R; Chow E; Rakovitch E; Laperriere N
Cochrane Database Syst Rev; 2006 Jul; (3):CD003869. PubMed ID: 16856022
[TBL] [Abstract][Full Text] [Related]
27. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
Olson JJ; Paleologos NA; Gaspar LE; Robinson PD; Morris RE; Ammirati M; Andrews DW; Asher AL; Burri SH; Cobbs CS; Kondziolka D; Linskey ME; Loeffler JS; McDermott M; Mehta MP; Mikkelsen T; Patchell RA; Ryken TC; Kalkanis SN
J Neurooncol; 2010 Jan; 96(1):115-42. PubMed ID: 19957013
[TBL] [Abstract][Full Text] [Related]
28. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
29. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.
Evens AM; Balasubramanian L; Gordon LI
Curr Treat Options Oncol; 2005 Jul; 6(4):289-96. PubMed ID: 15967082
[TBL] [Abstract][Full Text] [Related]
30. Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
Weitzel DH; Tovmasyan A; Ashcraft KA; Boico A; Birer SR; Roy Choudhury K; Herndon J; Rodriguiz RM; Wetsel WC; Peters KB; Spasojevic I; Batinic-Haberle I; Dewhirst MW
Environ Mol Mutagen; 2016 Jun; 57(5):372-81. PubMed ID: 27224425
[TBL] [Abstract][Full Text] [Related]
31. Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors.
Dehnad H; Kal HB; Stam T; Gademan IS; van Moorselaar RJ; van der Sanden BP
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):787-93. PubMed ID: 14529785
[TBL] [Abstract][Full Text] [Related]
32. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases.
Viala J; Vanel D; Meingan P; Lartigau E; Carde P; Renschler M
Radiology; 1999 Sep; 212(3):755-9. PubMed ID: 10478243
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
Miles DR; Smith JA; Phan SC; Hutcheson SJ; Renschler MF; Ford JM; Boswell GW
J Clin Pharmacol; 2005 Mar; 45(3):299-312. PubMed ID: 15703365
[TBL] [Abstract][Full Text] [Related]
34. Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
Lin TS; Naumovski L; Lecane PS; Lucas MS; Moran ME; Cheney C; Lucas DM; Phan SC; Miller RA; Byrd JC
Leuk Lymphoma; 2009 Dec; 50(12):1977-82. PubMed ID: 19860624
[TBL] [Abstract][Full Text] [Related]
35. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).
Zahedi Avval F; Berndt C; Pramanik A; Holmgren A
Biochem Biophys Res Commun; 2009 Feb; 379(3):775-9. PubMed ID: 19121624
[TBL] [Abstract][Full Text] [Related]
37. Management of brain metastases.
Soffietti R; Rudā R; Mutani R
J Neurol; 2002 Oct; 249(10):1357-69. PubMed ID: 12382150
[TBL] [Abstract][Full Text] [Related]
38. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
